Officer exculpation proposal and upcoming earnings put Braze in focus

Braze (BRZE) is back on investor radars after scheduling an annual meeting to vote on officer exculpation under updated Delaware law, just as the company prepares to report quarterly earnings after Wednesday’s market close.

At a share price of US$25.45, Braze has seen strong short term momentum, with a 7 day share price return of 16.96% and a 90 day share price return of 44.68%. However, the 1 year total shareholder return is down 29.09%, suggesting recent optimism is emerging against a weaker longer term backdrop as investors focus on the upcoming earnings update and the proposed officer exculpation vote.

If you are tracking how software and AI related themes are moving, this could be a good moment to broaden your watchlist with 34 AI small caps

With Braze trading at US$25.45, sitting at a discount to both analyst targets and some intrinsic value estimates while still loss making, you have to ask: is this a genuine reset, or are markets already pricing in future growth?

Most Popular Narrative: 27% Undervalued

At a last close of $25.45 against a widely followed fair value of $34.85, the most popular narrative sees considerable upside potential, hinging on how Braze executes its AI and platform expansion plans.

Braze's acquisition of OfferFit is expected to enhance AI-driven optimization capabilities and lead to revenue growth through deal size expansion and differentiation in the market. This investment should drive better earnings and net margins as OfferFit's sophisticated AI solutions integrate into Braze's platform.

Curious what kind of revenue runway, margin shift, and future earnings multiple need to line up for that fair value to make sense? The narrative leans on a specific growth cadence, a step change in profitability, and a valuation multiple usually reserved for higher profile software stories, all working together in a tight set of assumptions.

Result: Fair Value of $34.85 (UNDERVALUED)

However, that story can break if OfferFit integration drags on margins longer than expected, or if changing data laws push Braze's costs and complexity higher.

Next Steps

With sentiment clearly split between concern and optimism, this is the moment to look through the data yourself and decide where you stand, starting with the 2 key rewards and 2 important warning signs

Ready to hunt for more investment ideas?

If Braze has you thinking more broadly about opportunity and risk, do not stop here. Apply the same scrutiny across a wider set of stocks.

• Spot potential bargains early by scanning for quality companies trading below their implied value through the 46 high quality undervalued stocks.
• Build a steadier income stream by focusing on companies with robust payouts using the 10 dividend fortresses.
• Sleep a little easier by exploring companies that screen well on resilience and risk through the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.